製品: p15 INK4b Antibody
カタログ: AF0230
タンパク質の説明: Rabbit polyclonal antibody to p15 INK4b
アプリケーション: WB IHC IF/ICC
反応性: Human, Mouse, Rat
予測: Bovine, Horse, Rabbit, Dog
分子量: 14kDa; 15kD(Calculated).
ユニプロット: P42772
RRID: AB_2833405

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC: 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Bovine(100%), Horse(100%), Rabbit(100%), Dog(100%)
クローナリティ:
Polyclonal
特異性:
p15 INK4b Antibody detects endogenous levels of total p15 INK4b.
RRID:
AB_2833405
引用形式: Affinity Biosciences Cat# AF0230, RRID:AB_2833405.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

CDK inhibitory protein; CDK4B Inhibitor; Cdkn2b; CDN2B_HUMAN; Cyclin dependent kinase 4 inhibitor B; Cyclin Dependent Kinase Inhibitor 2B; Cyclin dependent kinase inhibitor 2B p15 inhibits CDK4; Cyclin dependent kinases 4 and 6 binding protein; Cyclin-dependent kinase 4 inhibitor B; INK4B; MTS 2; MTS-2; MTS2; Multiple tumor suppressor 2; Multiple Tumor Supressor 2; OTTHUMP00000021154; OTTHUMP00000021155; p14 CDK inhibitor; p14 INK4b; p14-INK4b; P15; p15 CDK inhibitor; p15 inhibits CDK4; p15 INK4b; p15-INK4b; p15INK4B; TP 15; TP15;

免疫原

免疫原:
Uniprot:
遺伝子(ID):
発現特異性:
P42772 CDN2B_HUMAN:

Isoform 2 is expressed in normal (keratinocytes, fibroblasts) and tumor cell lines.

タンパク質の説明:
p15-INK4B a potent inhibitor that nteracts strongly with CDK4 and CDK6. Potential effector of TGF-beta induced cell cycle arres
タンパク質配列:
MREENKGMPSGGGSDEGLASAAARGLVEKVRQLLEAGADPNGVNRFGRRAIQVMMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGARLDVRDAWGRLPVDLAEERGHRDVAGYLRTATGD

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Bovine
100
Dog
100
Rabbit
100
Chicken
75
Pig
0
Sheep
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P42772 基板として

Site PTM Type Enzyme
C74 S-Nitrosylation
R101 Methylation

研究背景

機能:

Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.

細胞の位置付け:

Cytoplasm.
Note: Also found in the nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Isoform 2 is expressed in normal (keratinocytes, fibroblasts) and tumor cell lines.

サブユニット構造:

Heterodimer of CDKN2B with CDK4 or CDK6. Isoform 2 does not interact with CDK4 nor CDK6.

タンパク質ファミリー:

Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.

研究領域

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

参考文献

1). Comprehensive Analysis of Cellular Senescence-Related Genes in Prognosis, Molecular Characterization and Immunotherapy of Hepatocellular Carcinoma. Biological Procedures Online, 2022 (PubMed: 36536279) [IF=6.4]

Application: WB    Species: Human    Sample: HCC tissues and cells

Fig. 6 Western Blot showed the protein expression difference of 5 signature genes in HCC tissues and cells. A Differential protein expression of 5 signature genes in 8 pairs of HCC tissues and paraneoplastic tissues. B Differential protein expression of 5 signature genes in normal liver cell (7702) and HCC cells (LM3, 97H, HepG2, 7721 and Hu7)

Application: IHC    Species: Human    Sample: HCC tissues and cells

Fig. 7 Staining images of five signature genes in HCC tissues and paraneoplastic tissues. Relative optical density scores were used to compare the differences between the two groups. A CBX2; B CDKN2B; C ETS2; D HMGA1; E UBE2S

2). ANRIL inhibits p15(INK4b) through the TGFβ1 signaling pathway in human esophageal squamous cell carcinoma. CELLULAR IMMUNOLOGY, 2014 (PubMed: 24747824) [IF=4.3]

Application: WB    Species:    Sample:


3). INK4 cyclin-dependent kinase inhibitors as potential prognostic biomarkers and therapeutic targets in hepatocellular carcinoma. Bioscience Reports, 2022 (PubMed: 35771229) [IF=4.0]

4). Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20. Journal of Cancer, 2019 (PubMed: 31417652) [IF=3.9]

Application: WB    Species: human    Sample: HEY and A2780 cells

Figure 5. |SMYD3 regulated ovarian cancer proliferation and apoptosis though SMYD3-H4K20me3-CDKN2A and SMYD3-H3K4me3-BIRC3, respectively. (A-B) The protein expression changes in the above 6 genes in the HEY and A2780 cell lines after SMYD3 knockdown in HEY and A2780 cells.

5). Comprehensive Analysis of INK4 Cyclin-Dependent Kinase Inhibitors in Hepatocellular Carcinoma. , 2022

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.